Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Statistics
Share Statistics
Beam Therapeutics has 99.84M shares outstanding. The number of shares has increased by 21.3% in one year.
Shares Outstanding | 99.84M |
Shares Change (YoY) | 21.3% |
Shares Change (QoQ) | 20.57% |
Owned by Institutions (%) | 98.87% |
Shares Floating | 88.04M |
Failed to Deliver (FTD) Shares | 8.8K |
FTD / Avg. Volume | 0.5% |
Short Selling Information
The latest short interest is 10.79M, so 13.03% of the outstanding shares have been sold short.
Short Interest | 10.79M |
Short % of Shares Out | 13.03% |
Short % of Float | 14.86% |
Short Ratio (days to cover) | 8.25 |
Valuation Ratios
The PE ratio is -5.42 and the forward PE ratio is -5.36. Beam Therapeutics's PEG ratio is -0.03.
PE Ratio | -5.42 |
Forward PE | -5.36 |
PS Ratio | 32.14 |
Forward PS | 3.4 |
PB Ratio | 2.78 |
P/FCF Ratio | -5.73 |
PEG Ratio | -0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Beam Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.22.
Current Ratio | 4.82 |
Quick Ratio | 4.82 |
Debt / Equity | 0.22 |
Debt / EBITDA | -0.39 |
Debt / FCF | -0.45 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $131.51K |
Profits Per Employee | $-780K |
Employee Count | 483 |
Asset Turnover | 0.06 |
Inventory Turnover | n/a |
Taxes
Income Tax | 39K |
Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by -37.74% in the last 52 weeks. The beta is 1.91, so Beam Therapeutics's price volatility has been higher than the market average.
Beta | 1.91 |
52-Week Price Change | -37.74% |
50-Day Moving Average | 26.15 |
200-Day Moving Average | 25.67 |
Relative Strength Index (RSI) | 31.79 |
Average Volume (20 Days) | 1.77M |
Income Statement
In the last 12 months, Beam Therapeutics had revenue of 63.52M and earned -376.74M in profits. Earnings per share was -4.58.
Revenue | 63.52M |
Gross Profit | 63.52M |
Operating Income | -415.57M |
Net Income | -376.74M |
EBITDA | -415.57M |
EBIT | -415.57M |
Earnings Per Share (EPS) | -4.58 |
Balance Sheet
The company has 281.97M in cash and 161.43M in debt, giving a net cash position of 120.54M.
Cash & Cash Equivalents | 281.97M |
Total Debt | 161.43M |
Net Cash | 120.54M |
Retained Earnings | -1.57B |
Total Assets | 1.1B |
Working Capital | 696.08M |
Cash Flow
In the last 12 months, operating cash flow was -347.25M and capital expenditures -8.95M, giving a free cash flow of -356.19M.
Operating Cash Flow | -347.25M |
Capital Expenditures | -8.95M |
Free Cash Flow | -356.19M |
FCF Per Share | -4.33 |
Margins
Gross margin is 100%, with operating and profit margins of -654.25% and -593.13%.
Gross Margin | 100% |
Operating Margin | -654.25% |
Pretax Margin | -593.06% |
Profit Margin | -593.13% |
EBITDA Margin | -654.25% |
EBIT Margin | -654.25% |
FCF Margin | -560.77% |
Dividends & Yields
BEAM pays an annual dividend of $1.12, which amounts to a dividend yield of 4.8%.
Dividend Per Share | $1.12 |
Dividend Yield | 4.8% |
Dividend Growth (YoY) | 0% |
Payout Ratio | -24.56% |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for BEAM is $42, which is 127.3% higher than the current price. The consensus rating is "Buy".
Price Target | $42 |
Price Target Difference | 127.3% |
Analyst Consensus | Buy |
Analyst Count | 12 |
Scores
Altman Z-Score | 0.44 |
Piotroski F-Score | 2 |